• Successful in vivo studies of its lead arginine modulator drug candidate
• Tested in 12 mouse models of most prevalent cancers
• Significant activity demonstrated in cancer model of melanoma
• Relationship with the Baker Heart and Diabetes Institute expanded
MELBOURNE Australia, 19 February 2018: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, today said pre-clinical in vivo data for its arginine modulator drug candidate had demonstrated anti-tumor activity in 12 different cancer mouse models of the most prevalent cancers, with significant activity in a melanoma cancer model.
For further information please download PDF attached:
Download this document
